Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)

Abstract

The aim of this observational prospective study was to evaluate the switch from phytotherapy to tamsulosin 0.4 mg once daily (o.d.) on efficacy, sexual function and tolerability in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) who have a poor response to at least 4 weeks of phytotherapy. The switch to tamsulosin 0.4 mg o.d. improves LUTS and related quality of life. Sexual function is also slightly improved. Tamsulosin is as well tolerated as phytotherapy and abnormal ejaculation appears to be no problem. Tamsulosin is perceived by both patients and urologists to be superior to preceding phytotherapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Garraway WM, Collins GN, Lee RJ . High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–471.

    Article  CAS  Google Scholar 

  2. Chute CG et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85–89.

    Article  CAS  Google Scholar 

  3. Chapple CR . Introduction and concluding remarks. Eur Urol 1999; 36 (Suppl 3): 1–6.

    Article  Google Scholar 

  4. Djavan B, Chapple C, Milani S, Marberger M . State of the art on the efficacy and tolerability of α1-AR antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Urology 2004; 64: 1081–1088.

    Article  Google Scholar 

  5. IMS MIDA, data MAT 2004.

  6. Farmer R, Hutchison A, Chapple C . Comparison of the treatment regimes of new and existing LUTS/BPH patients in 6 European countries. Eur Urol 2004; 3: 60 (abstract 230).

    Article  Google Scholar 

  7. Chatelain Ch et al. (eds.) 5th International Consultation on BPH. Recommendations of the International Scientific Committee: Evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. Benign Prostatic Hyperplasia, 5th Iternational Consultation on Benign Prostatic Hyperplasia (BPH) June 25–28, 2000 Paris. Plymbridge Distributors Ltd: Plymouth, 2001, pp 519–534.

  8. AUA practice guidelines committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530–547.

  9. Barry MJ et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549–1557.

    Article  CAS  Google Scholar 

  10. Michel MC, Bressel HU, Mehlburger L, Goepel M . Tamsulosin, real life clinical experience in 19,365 patients. Eur Urol 1998; 34 (Suppl 2): 37–45.

    Article  CAS  Google Scholar 

  11. Debruyne F et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year international randomised international study. Eur Urol 2002; 41: 497–506.

    Article  CAS  Google Scholar 

  12. Grasso M et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995; 48: 97–103.

    CAS  PubMed  Google Scholar 

  13. Abbou CC, Hoznek A, Carthy CM . Alfuzosin an uroselective alpha 1 blocker versus Pygeum afrikanum, a plant extract: a randomised controlled trial in patients with symptomatic benign prostatic hypertrophy (BPH). Eur Urol 1996; 30 (Suppl 26): 77 (abstract 241).

    Google Scholar 

  14. Chapple CR et al. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomised, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155–167.

    CAS  PubMed  Google Scholar 

  15. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892–900.

    Article  CAS  Google Scholar 

  16. Lepor H, for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia. Placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: 901–906.

    Article  CAS  Google Scholar 

  17. Narayan P, Tewari A, members of the United States 93-01 Study Group. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 1701–1706.

    Article  CAS  Google Scholar 

  18. Speakman MJ et al. Tamsulosin is effective in patients with lower urinary tract symptoms/benign prostatic hyperplasia, irrespective of prostate size. Eur Urol Suppl 2003; 2: 75 (abstract 289).

    Article  Google Scholar 

  19. Höfner K et al. Tamsulosin 0.4 mg o.d.: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335–341.

    Article  Google Scholar 

  20. Debruyne F, Narayan P . Tamsulosin improves sexual function with minimal abnormal ejaculation in patients treated for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int 2002; 90 (Suppl 2): 12 (P.1.2.01).

    Google Scholar 

Download references

Acknowledgements

This study was sponsored by Boehringer Ingelheim Pharma GmbH & Co. KG.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A J Gross.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gross, A., Busse, M., Leonard, J. et al. Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Prostate Cancer Prostatic Dis 8, 210–214 (2005). https://doi.org/10.1038/sj.pcan.4500803

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500803

Keywords

Search

Quick links